Navigation Links
Quest Diagnostics Sets New Date to Report Fourth Quarter and Full Year 2007 Results
Date:1/17/2008

Reaffirms Previous Guidance for 2007

MADISON, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it will report results for the fourth quarter and year ended December 31, 2007 and provide financial guidance for 2008 on February 21, 2008, instead of the previously scheduled date of January 29.

The company is rescheduling its report of fourth quarter and full-year 2007 results in order to provide time to attempt to make further progress in its ongoing effort to settle with the government claims associated with the government's investigation in connection with NID, a test kit manufacturing subsidiary the company closed in 2006. While the company is working diligently to reach such a settlement prior to its report of earnings for the fourth quarter and year ended December 31, 2007, there can be no assurance as to when or whether a settlement may be reached, or as to its terms. Additional information regarding this matter is available in the company's September 30, 2007 Quarterly Report on Form 10-Q, including Footnote 7 to the Financial Statements.

The company reaffirms its 2007 guidance for revenues of between $6.6 billion and $6.7 billion, and earnings per diluted share from continuing operations of between $2.84 and $2.91, before $0.04 per share in special charges recorded in the first quarter of 2007.

Quest Diagnostics will hold its fourth quarter conference call on February 21, 2008 at 8:30 A.M. Eastern Time. A simulcast of the call is available by dialing 210-839-8500 -- PASSCODE: 3214469 and via the Internet at: http://www.questdiagnostics.com. Registered analysts may access the call at: http://www.streetevents.com. In addition, a replay of the call will be available from 10:30 A.M. on February 21 through 11 P.M. on March 20, 2008 to investors in the U.S. by dialing 866-393-1025. Investors outside the U.S. may dial 203-369- 0451. No password is required for either number.

About Quest Diagnostics

Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at http://www.questdiagnostics.com.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the Company include, but are not limited to, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business" in Part I, Item 1, "Risk Factors" and "Cautionary Statement for Purposes of the 'Safe Harbor' Provisions of the Private Securities Litigation Reform Act of 1995" in Item I, Part 1A, "Legal Proceedings" in Part I, Item 3, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 and "Quantitative and Qualitative Disclosures About Market Risk" in Part II, Item 7A in the Quest Diagnostics 2006 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the Company's 2007 Quarterly Reports on Form 10-Q and other items throughout the Form 10-K and the Company's 2007 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SciQuest Continues to Surpass Milestones for Customer Wins, Growth and Market Share; Remains Clear Eprocurement Leader for Academic and Research-Centric Organizations
2. Quest Diagnostics to Speak at the 26th Annual JPMorgan Healthcare Conference
3. ADM, MGSC and ISGS Announce Carbon Sequestration Project
4. SleepQuest Launches Updated Web Site
5. Quest Diagnostics Declares Quarterly Cash Dividend
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
8. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
9. Sinovac Requests Extension for Annual Shareholders Meeting
10. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
11. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):